This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05848258
Recruitment Status : Recruiting
First Posted : May 8, 2023
Last Update Posted : February 29, 2024
Rigel Pharmaceuticals
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 25, 2026
Estimated Study Completion Date : July 15, 2026